|
Oct 4
|
3 Top Stocks That Could Still Rocket Higher in 2024
|
|
Oct 3
|
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
|
|
Oct 1
|
5 FDA decisions to watch in the fourth quarter
|
|
Sep 30
|
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
|
|
Sep 30
|
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
|
|
Sep 27
|
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
|
|
Aug 30
|
Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug
|
|
Aug 30
|
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
|
|
Aug 30
|
BridgeBio Pharma Reports Positive Additional Data From Phase 3 Study of Acoramidis; Shares Rise
|
|
Aug 30
|
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
|
|
Aug 29
|
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
|
|
Aug 28
|
BridgeBio Pharma to Participate in September Investor Events
|
|
Aug 26
|
BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
|
|
Jul 23
|
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
|
|
Jun 27
|
BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
|
|
Jun 18
|
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
|
|
May 29
|
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
|
May 24
|
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
|
|
May 22
|
Party Time: Brokers Just Made Major Increases To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Earnings Forecasts
|
|
May 14
|
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
|